| Trial | Sponsor | Phase | Status | Primary completion |
|---|
| A Long-Term Safety and Efficacy Study of Verekitug (UPB-101) in Adult Participants With Severe Asthma (VALOUR)NCT06966479 | UPB | Phase 2 | Active not recruiting | 2027-09Estimated |
| Safety and Efficacy of VDPHL01 in Males With AGANCT06972264 | MANE | Phase 3 | Active not recruiting | 2026-12Estimated |
| Efficacy and Safety of MSC-NTF (NurOwn) in Participants With Early Symptomatic ALS and Moderate Disease Presentation in ALS (ENDURANCE STUDY)NCT06973629 | Brainstorm-Cell Therapeutics | Phase 3 | Not yet recruiting | 2028-11-01Estimated |
| A Study to Assess the Safety and Efficacy of Oral LPCN 1154A in Women With Severe PPDNCT06979544 | LPCN | Phase 3 | Completed | 2026-01-16Actual |
| A Study to Assess the Efficacy and Safety of Verekitug in Participants With COPDNCT06981078 | UPB | Phase 2 | Active not recruiting | 2027-10Estimated |
| Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast CancerNCT06982521 | RLAY | Phase 3 | Recruiting | 2028-04-30Estimated |
| Atacicept in Multiple Glomerular DiseasesNCT06983028 | VERA | Phase 2 | Recruiting | 2027-11Estimated |
| A Phase 2, Open-Label Study of DISC-3405 in Participants With Polycythemia Vera (PV)NCT06985147 | IRON | Phase 2 | Active not recruiting | 2027-07Estimated |
| RECLAIM STUDY: Phase 2 Study of the Efficacy and Safety of Pemvidutide in the Treatment of Alcohol Use Disorder (AUD) in Subjects With Obesity or OverweightNCT06987513 | ALT | Phase 2 | Completed | 2026-07-30Actual |
| Phase 2 Study of ADX-038 in Complement-Mediated Kidney DiseaseNCT06989359 | ADRX | Phase 2 | Recruiting | 2030-04-30Estimated |
| Phase 2 Study of ADX-038 in Participants With Geographic AtrophyNCT06990269 | ADRX | Phase 2 | Recruiting | 2030-02-28Estimated |
| A Phase 3 Study to Evaluate the Efficacy and Safety of Intravitreal KSI-101 in Participants With Macular Edema Secondary to Inflammation (MESI) - PEAKNCT06990399 | KOD | Phase 3 | Recruiting | 2027-04Estimated |
| A Dose-ranging Study of TTI-0102 in Adults and Children With Leigh Syndrome Spectrum (LSS)NCT06990984 | Thiogenesis Therapeutics, Inc. | Phase 2 | Not yet recruiting | 2027-06Estimated |
| AlloNK®, an Allogeneic Non-genetically Modified, Cord Blood-derived NK Cell Therapy, in Combination With Rituximab, Studied in Relapsing Forms of B-cell Dependent Rheumatologic Diseases.NCT06991114 | ARTV | Phase 2 | Recruiting | 2028-01Estimated |
| Tibulizumab Skin Healing and Inflammation Evaluation for Lasting DefenseNCT06993610 | Zura Bio Inc | Phase 2 | Active not recruiting | 2026-09-18Actual |
| Efficacy and Safety of TYRA-300 in Participants With FGFR3 Altered Low Grade, Intermediate Risk Non-Muscle Invasive Bladder CancerNCT06995677 | TYRA | Phase 2 | Recruiting | 2028-02Estimated |
| A Phase 3 Study to Evaluate the Efficacy and Safety of Intravitreal KSI-101 in Participants With Macular Edema Secondary to Inflammation (MESI) - PINNACLENCT06996080 | KOD | Phase 3 | Recruiting | 2027-02Estimated |
| Safety Study of Roflumilast Cream 0.05% in Infants Aged 3 Months to Less Than 2 Years With Atopic DermatitisNCT06998056 | ARQT | Phase 2 | Completed | 2025-12-04Actual |
| Double-blind, Randomized Trial of PRAX-628 in Adults With Focal Seizures to Evaluate Efficacy and Safety (POWER1)NCT06999902 | Praxis Precision Medicines | Phase 2, Phase 3 | Completed | 2026-05-14Actual |
| Ataciguat for Slowing the Progression of Moderate Calcific Aortic Valve Stenosis: A Randomized, Placebo Controlled StudyNCT07001800 | KARD | Phase 2, Phase 3 | Recruiting | 2028-08-31Estimated |
| Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AMLNCT07007312 | KURA | Phase 3 | Recruiting | 2031-11Estimated |
| ASPEN-09-03: A Study of Evorpacept in Combination With Trastuzumab and Chemotherapy in Metastatic HER2-Positive Breast CancerNCT07007559 | ALX Oncology Inc. | Phase 2 | Recruiting | 2027-12Estimated |
| A Study to Evaluate the Long-term Safety, Tolerability, and Efficacy of Subcutaneous Sonelokimab in Participants With Moderate to Severe Hidradenitis SuppurativaNCT07007637 | MoonLake Immunotherapeutics AG | Phase 3 | Enrolling by invitation | 2028-06-13Estimated |
| RESTORE TRIAL: Study of the Efficacy and Safety of Pemvidutide in the Treatment of Alcohol-Associated Liver Disease (ALD)NCT07009860 | ALT | Phase 2 | Active not recruiting | 2027-09-30Estimated |
| Phase 2/3 Study of Participants With Recurrent Pericarditis Evaluating the Efficacy and Safety of KPL-387NCT07010159 | KNSA | Phase 2, Phase 3 | Recruiting | 2027-12-31Estimated |
| A Clinical Trial for Participants With DEE to Assess Efficacy, Safety, Tolerability, and PK of RelutrigineNCT07010471 | Praxis Precision Medicines | Phase 3 | Active not recruiting | 2026-12Estimated |
| ATI-045 Versus Placebo in Patients With Moderate-to-Severe Atopic DermatitisNCT07011706 | ACRS | Phase 2 | Active not recruiting | 2026-09-21Actual |
| Study of Casdatifan and Cabozantinib Versus Placebo and Cabozantinib in Patients With Advanced Clear Cell Renal Cell CarcinomaNCT07011719 | RCUS | Phase 3 | Recruiting | 2028-04Estimated |
| A Study of Long-acting Antibodies Alone and in Combinations for Moderate to Severe Ulcerative ColitisNCT07012395 | SYRE | Phase 2 | Recruiting | 2027-06Estimated |
| Neoadjuvant Darovasertib in Primary Uveal MelanomaNCT07015190 | IDEAYA Biosciences | Phase 3 | Recruiting | 2030-10Estimated |
Trial details
- Registry ID
- NCT06966479
- Phase
- Phase 2
Trial details
- Registry ID
- NCT06972264
- Phase
- Phase 3
Trial details
- Registry ID
- NCT06973629
- Phase
- Phase 3
Trial details
- Registry ID
- NCT06979544
- Phase
- Phase 3
Trial details
- Registry ID
- NCT06981078
- Phase
- Phase 2
Trial details
- Registry ID
- NCT06982521
- Phase
- Phase 3
Trial details
- Registry ID
- NCT06983028
- Phase
- Phase 2
Trial details
- Registry ID
- NCT06985147
- Phase
- Phase 2
Trial details
- Registry ID
- NCT06987513
- Phase
- Phase 2
Trial details
- Registry ID
- NCT06989359
- Phase
- Phase 2
Trial details
- Registry ID
- NCT06990269
- Phase
- Phase 2
Trial details
- Registry ID
- NCT06990399
- Phase
- Phase 3
Trial details
- Registry ID
- NCT06990984
- Phase
- Phase 2
Trial details
- Registry ID
- NCT06991114
- Phase
- Phase 2
Trial details
- Registry ID
- NCT06993610
- Phase
- Phase 2
Trial details
- Registry ID
- NCT06995677
- Phase
- Phase 2
Trial details
- Registry ID
- NCT06996080
- Phase
- Phase 3
Trial details
- Registry ID
- NCT06998056
- Phase
- Phase 2
Trial details
- Registry ID
- NCT06999902
- Phase
- Phase 2, Phase 3
Trial details
- Registry ID
- NCT07001800
- Phase
- Phase 2, Phase 3
Trial details
- Registry ID
- NCT07007312
- Phase
- Phase 3
Trial details
- Registry ID
- NCT07007559
- Phase
- Phase 2
Trial details
- Registry ID
- NCT07007637
- Phase
- Phase 3
Trial details
- Registry ID
- NCT07009860
- Phase
- Phase 2
Trial details
- Registry ID
- NCT07010159
- Phase
- Phase 2, Phase 3
Trial details
- Registry ID
- NCT07010471
- Phase
- Phase 3
Trial details
- Registry ID
- NCT07011706
- Phase
- Phase 2
Trial details
- Registry ID
- NCT07011719
- Phase
- Phase 3
Trial details
- Registry ID
- NCT07012395
- Phase
- Phase 2
Trial details
- Registry ID
- NCT07015190
- Phase
- Phase 3
Primary completion marks the end of data collection for the main study measures, not a results publication date.